Literature DB >> 18977667

Carcinoma of unknown primary (CUP).

Nicholas Pavlidis1, Karim Fizazi.   

Abstract

Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests as an heterogeneous group of mainly epithelial cancers recognised by distinct clinicopathological entities. The diagnostic work-up includes extensive histopathology investigations and modern imaging technology. Nevertheless, the primary tumour remains undetected most of the time. Molecular diagnosis with DNA microarrays demonstrates high sensitivity, but its prognostic contribution is still uncertain. Certain clinicopathological CUP entities are considered as favourable sub-sets responding to systemic platinum-based chemotherapy or managed by locoregional treatment. These sub-sets are: the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, peritoneal papillary serous adenocarcinomatosis in females, poorly differentiated neuroendocrine carcinomas, isolated axillary node adenocarcinomas in females or cervical nodal involvement by a squamous cell carcinoma. Patients who belong to the non-favourable sub-sets have a worse prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18977667     DOI: 10.1016/j.critrevonc.2008.09.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  63 in total

1.  Accurate classification of metastatic brain tumors using a novel microRNA-based test.

Authors:  Wolf C Mueller; Yael Spector; Tina Bocker Edmonston; Brianna St Cyr; Diana Jaeger; Ulrike Lass; Ranit Aharonov; Shai Rosenwald; Ayelet Chajut
Journal:  Oncologist       Date:  2011-01-27

2.  Metastatic transitional cell carcinoma in proximal humerus of a dog.

Authors:  Sarah Malek; Kimberly A Murphy; Stephanie G Nykamp; Rachel Allavena
Journal:  Can Vet J       Date:  2011-09       Impact factor: 1.008

Review 3.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

Review 4.  18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review.

Authors:  Anne Kirstine Hundahl Moller; Annika Loft; Anne Kiil Berthelsen; Karen Damgaard Pedersen; Jesper Graff; Charlotte Birk Christensen; Katharina Perell; Bodil Laub Petersen; Gedske Daugaard
Journal:  Oncologist       Date:  2011-03-22

Review 5.  Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.

Authors:  Kyung Won Kim; Katherine M Krajewski; Jyothi P Jagannathan; Mizuki Nishino; Atul B Shinagare; Jason L Hornick; Nikhil H Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

6.  Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.

Authors:  Federico A Monzon; Fabiola Medeiros; Maureen Lyons-Weiler; W David Henner
Journal:  Diagn Pathol       Date:  2010-01-13       Impact factor: 2.644

7.  Assessment of engineered cells using CellNet and RNA-seq.

Authors:  Arthur H Radley; Remy M Schwab; Yuqi Tan; Jeesoo Kim; Emily K W Lo; Patrick Cahan
Journal:  Nat Protoc       Date:  2017-04-27       Impact factor: 13.491

8.  Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience.

Authors:  Margareta Randén; Maria Helde-Frankling; Sara Runesdotter; Peter Gunvén
Journal:  Med Oncol       Date:  2013-09-18       Impact factor: 3.064

Review 9.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 10.  FDG PET/CT in carcinoma of unknown primary.

Authors:  Thomas C Kwee; Sandip Basu; Gang Cheng; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-31       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.